Fundamental Analysis of ARVINAS INC(NASDAQ:ARVN) stock

Fundamental Rating

Overall ARVN gets a fundamental rating of 3 out of 10. We evaluated ARVN against 194 industry peers in the Pharmaceuticals industry. ARVN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ARVN is valued quite expensive, but it does show an excellent growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

ARVN had negative earnings in the past year.

ARVN had a negative operating cash flow in the past year.

In the past 5 years ARVN always reported negative net income.

ARVN had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -44.65%, ARVN is in line with its industry, outperforming 42.19% of the companies in the same industry.

The Return On Equity of ARVN (-88.92%) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
ROA	-44.65%
ROE	-88.92%
ROIC	N/A

ROA(3y)-20.83%

ROA(5y)-20.49%

ROE(3y)-43.36%

ROE(5y)-35.94%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ARVN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ARVN does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, ARVN has more shares outstanding

Compared to 5 years ago, ARVN has more shares outstanding

ARVN has a better debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -0.54, we must say that ARVN is in the distress zone and has some risk of bankruptcy.

ARVN has a Altman-Z score of -0.54. This is comparable to the rest of the industry: ARVN outperforms 47.40% of its industry peers.

A Debt/Equity ratio of 0.00 indicates that ARVN is not too dependend on debt financing.

ARVN has a Debt to Equity ratio of 0.00. This is comparable to the rest of the industry: ARVN outperforms 59.90% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-0.54

ROIC/WACCN/A

WACC9.07%

2.3 Liquidity

A Current Ratio of 4.17 indicates that ARVN has no problem at all paying its short term obligations.

ARVN has a Current ratio (4.17) which is in line with its industry peers.

ARVN has a Quick Ratio of 4.17. This indicates that ARVN is financially healthy and has no problem in meeting its short term obligations.

The Quick ratio of ARVN (4.17) is better than 61.98% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	4.17
Quick Ratio	4.17

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ARVN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.55%, which is quite good.

The Revenue has grown by 69.08% in the past year. This is a very strong growth!

The Revenue has been growing by 40.57% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)15.55%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%42.37%

Revenue 1Y (TTM)69.08%

Revenue growth 3Y53.27%

Revenue growth 5Y40.57%

Sales Q2Q%195.95%

3.2 Future

ARVN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.44% yearly.

The Revenue is expected to grow by 32.76% on average over the next years. This is a very strong growth

EPS Next Y49.56%

EPS Next 2Y12.64%

EPS Next 3Y7.43%

EPS Next 5Y16.44%

Revenue Next Year53.46%

Revenue Next 2Y10.6%

Revenue Next 3Y9.28%

Revenue Next 5Y32.76%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ARVN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ARVN. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y12.64%

EPS Next 3Y7.43%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ARVN!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ARVINAS INC

NASDAQ:ARVN (11/22/2024, 8:23:57 PM)

After market: 26.4 +0.54 (+2.09%)

25.86

+0.75 (+2.99%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap1.78B

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-44.65%
ROE	-88.92%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.24

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	4.17
Quick Ratio	4.17
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)15.55%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y49.56%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)69.08%

Revenue growth 3Y53.27%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

ARVINAS INC (ARVN)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens